Triple stem cell infusion alleviated graft-versus-host disease and improves outcomes in unmanipulated haploidentical hematopoietic stem cell transplantation.

干细胞 造血干细胞移植 移植物抗宿主病 移植 造血 造血干细胞 免疫学 医学 生物 内科学 细胞生物学
作者
Fang Hua,S R Zhang,Xiaomei Zhang,Yan Deng,Ying Han,Sihan Lai,Ying He,Lei Ma,Xupai Zhang,Dan Chen,Yi Su,Jian Xiao,Ling Zhang,Yongfeng Yang,Huang Rong,Haiyan Hu,Mingli Chen,Guangcui He,Hao Yao,Hai Yi
出处
期刊:PubMed [National Institutes of Health]
卷期号:34: 9636897251359786-9636897251359786
标识
DOI:10.1177/09636897251359786
摘要

Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) provides cure opportunity for patients requiring prompt allogeneic HSCT but failing to identify well-matched donor, but its outcomes are potentially impaired by increased transplant-related mortality (TRM). We performed haplo-HSCT using granulocyte colony-stimulating factor (G-CSF)-primed peripheral blood stem cells (PBSCs), umbilical cord mesenchymal stem cells (UC-MSCs) and third-party unrelated umbilical cord blood (UCB) stem cells. Modified "Beijing protocol" were performed in this study. All of the patients were transplanted by Busulfan or TBI-based regimen. Anti-thymocyte globulin were used to T-cell depletion in vivo. Cyclosporine, mycophenolate mofetil, and short course methotrexate were used to prevent graft-versus-host disease (GVHD). One hundred and sixty-five patients with hematological disorders undergoing haplo-HSCT from Jan 2021 to Nov 2023 were included in this study. The median time of neutrophil engraftment were 12 days (range: 9-25 days), and the median time of platelet engraftment were 13 days (range: 6-50 days). Full haploidentical donor chimerism were obtained within 30 days. No evidence of UCB chimerism was found. Twenty-five patients developed acute GVHD. The incidence of grade II-IV and grade III-IV acute GVHD was 12.73% and 6.67%, respectively. Twenty-eight patients developed chronic GVHD, 10 were limited (6.06%) and 18 were extensive (10.91%). The TRM is total of 26 deaths (15.8%) and the cumulative incidence of relapse (CIR) is total of 17 deaths (11.8%) occurred as of the statistical period. The 2 years overall survival (OS) rate is 72.96%. The median overall survival rate was not reached. Haplo-HSCT performed by PBSCs, UC-MSCs and UCB "triple-infusion" achieved excellent outcomes, and need to explored in a larger cohort.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
ccc发布了新的文献求助10
1秒前
真诚发布了新的文献求助10
1秒前
cdercder的应助被李时云采纳,获得10
2秒前
crash完成签到,获得积分10
2秒前
2秒前
Nole的应助被可靠碧萱采纳,获得10
3秒前
leehom发布了新的文献求助10
3秒前
luyjabc完成签到,获得积分10
3秒前
奶糖味的薯片完成签到 ,获得积分10
4秒前
4秒前
4秒前
所所的应助被糖葫芦采纳,获得10
5秒前
6秒前
lsx发布了新的文献求助10
6秒前
7秒前
32kekediffers发布了新的文献求助10
7秒前
hu发布了新的文献求助10
7秒前
8秒前
FashionBoy的应助被丁真人采纳,获得10
9秒前
宁静的夏天给布二的求助进行了留言
9秒前
mali123发布了新的文献求助10
9秒前
9秒前
夏目发布了新的文献求助10
10秒前
优美的问芙完成签到,获得积分10
10秒前
丘比特的应助被红枣脆脆鲨采纳,获得10
10秒前
11秒前
ding的应助被浮云客采纳,获得10
11秒前
ASL完成签到,获得积分10
11秒前
CipherSage的应助被菜菜彼得采纳,获得10
11秒前
12秒前
brmxj完成签到,获得积分10
12秒前
12秒前
twooo完成签到 ,获得积分10
12秒前
QuanlongWang发布了新的文献求助10
12秒前
北望发布了新的文献求助10
13秒前
pp完成签到,获得积分10
14秒前
爆米花的应助被ccxr采纳,获得30
15秒前
怡然新梅完成签到,获得积分10
15秒前
春日午后完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611